Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Bendamustine Plus Rituximab Versus CHOP Plus Rituximab

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Jurgen Barth, University of Giessen
ClinicalTrials.gov Identifier:
NCT00991211
First received: October 6, 2009
Last updated: March 13, 2012
Last verified: October 2009